首页> 美国卫生研究院文献>Canadian Medical Association Journal >An Investigation of the Hemorrhagic Diathesis in Patients Receiving Coumarin and Indanedione Anticoagulants
【2h】

An Investigation of the Hemorrhagic Diathesis in Patients Receiving Coumarin and Indanedione Anticoagulants

机译:香豆素和茚二酮抗凝剂患者出血素质的调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coagulation studies were carried out on 10 patients who bled during anticoagulant therapy, in whom no other underlying cause for bleeding could be demonstrated, and 10 patients with similar degrees of hypoprothrombinemia who were not bleeding. The average age and sex distribution of the two groups was similar, and no association was noted between the occurrence of hemorrhage and the type of anticoagulant used, the duration of treatment or the nature of the underlying disease. Comparison of the results revealed no differences in the levels of factors II, VII, IX and X or in the glass and silicone (Siliclad) clotting time, the thromboplastin generation test and Thrombotest. It was concluded that all patients on anticoagulant drugs whose prothrombin time is in the therapeutic range or longer are potential bleeders and that one cannot necessarily predict those who will bleed on the basis of coagulation studies.
机译:对10例在抗凝治疗期间出血的患者进行了凝血研究,其中未发现其他潜在的出血原因,另外10例具有相似程度的低凝血酶原血症的患者未出血。两组的平均年龄和性别分布相似,出血与使用的抗凝剂类型,治疗时间或潜在疾病的性质之间没有相关性。结果比较表明,因子II,VII,IX和X的水平或玻璃和硅树脂(Siliclad)的凝结时间,凝血活酶生成测试和Thrombotest均无差异。结论是,所有凝血酶原时间在治疗范围或更长时间内使用抗凝药物的患者都是潜在的出血患者,不能根据凝血研究预测那些会出血的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号